Cheng Wei Wang
About Cheng Wei Wang
Cheng Wei Wang is a Scientist III/Supervisor at Precision BioSciences, Inc. in Durham, North Carolina, where he leads the design and validation of histological assays for gene editing programs.
Work at Precision BioSciences
Cheng Wei Wang currently holds the position of Scientist III/Supervisor at Precision BioSciences, Inc., a role he has occupied since 2022. In this capacity, he leads the design, optimization, and validation of histological assays using multiplex immunohistochemical and immunofluorescence techniques. His work supports in vivo gene editing programs, demonstrating his expertise in the field. Previously, he served as Scientist I at the same company from 2020 to 2022, where he contributed to various projects in Durham, North Carolina.
Education and Expertise
Cheng Wei Wang earned his Doctor of Philosophy (PhD) from National Yang Ming University. He also holds a Master's degree in Biochemistry and Molecular Biology from National Cheng Kung University. His educational background provides a strong foundation for his research and development work in gene editing and histological applications. His extensive hands-on experience with advanced microscopy techniques and digital scanning further enhances his expertise in the field.
Background in Academia and Research
Prior to his current role, Cheng Wei Wang worked at Academia Sinica in Taiwan as a Postdoctoral Fellow from 2012 to 2013. He then moved to the University of California, Los Angeles (UCLA), where he held the positions of Postdoctoral Researcher from 2013 to 2018 and Assistant Project Scientist from 2018 to 2020. His time at UCLA involved significant contributions to research projects, further developing his skills in histological assays and gene editing.
Collaboration and Project Involvement
In his current role, Cheng Wei Wang collaborates closely with pathologists and scientists from various functional teams. This collaboration ensures high-quality assay performance in preclinical gene therapy projects. He is also responsible for drafting, reviewing, and editing preclinical in vivo studies specifically related to gene editing programs, showcasing his integral role in advancing research initiatives.